CCM
NMRA icon

Cutter Capital Management’s Neumora Therapeutics NMRA Stock Holding History

Cutter Capital Management’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-150,000
Closed -$1.59M – 27
2024
Q4 		$1.59M Buy
+150,000
New +$1.8M 0.65% 21

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return

Cutter Capital Management's NMRA Position: Q1 2025 in Review

Cutter Capital Management sold out of Neumora Therapeutics (NMRA) in Q1 2025, closing a stake of 150,000 shares — an estimated $1.59M sold.

Cutter Capital Management first reported a position in NMRA in Q4 2024 and held it in 1 quarter. The position peaked at $1.59M in Q4 2024. 115 funds tracked by Wall St. Rank hold NMRA as of Q1 2025.

  • Cutter Capital Management reported no remaining Neumora Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Cutter Capital Management sold 150,000 Neumora Therapeutics shares in Q1 2025, an estimated $1.59M.
  • Cutter Capital Management first reported a position in Neumora Therapeutics in Q4 2024 and held it in 1 quarter.
  • Cutter Capital Management's Neumora Therapeutics position peaked at $1.59M in Q4 2024.
  • 115 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2025.

Based on Cutter Capital Management's 13F filing for Q1 2025, filed 15 May 2025.